معرفی
Professor Cemil Bilir is a distinguished Medical Oncology specialist at Recep Tayyip Erdoğan University's Faculty of Medicine, Department of Internal Medicine. With extensive clinical and research experience, he contributes significantly to cancer research and patient care in Turkey.
His educational background includes:
- Graduated from Istanbul University Faculty of Medicine (2004)
- Completed Internal Medicine specialization (2005-2010)
- Finished Medical Oncology subspecialty training (2010-2013)
Professor Bilir's research focuses on molecular mechanisms in cancer progression, particularly examining TGF-β, IL-6/JAK/STAT3, and TLR4 signaling pathways in breast, lung, and prostate cancers. His work bridges basic science discoveries with clinical applications, investigating how natural compounds like curcumin and established therapies like zoledronic acid affect cancer progression and patient outcomes. Recent studies have explored cancer cachexia mechanisms, treatment response biomarkers, and the relationship between renal function and chemotherapy efficacy.
His publication record shows consistent productivity with research spanning from 2006 to 2020, demonstrating evolving expertise from general internal medicine topics to specialized oncology research. The most recent publications (2018-2020) reveal a strong focus on molecular oncology and targeted therapies.
Professor Bilir's scientific recognition includes:
- 3rd Prize in Best Research (2016)
As an active researcher and clinician, Professor Bilir contributes to the Turkish Oncology Group and participates in multi-institutional cancer research across Turkey. His work provides valuable insights into cancer treatment optimization and biomarker discovery for Turkish patient populations.
